US Partnership Expands to Provide Lenacapavir HIV Drug to One Million
Summary
The U.S. Department of State announced an expansion of its partnership with Gilead Sciences and The Global Fund to provide lenacapavir (LEN), a twice-yearly injectable HIV prevention medication, to an additional one million people in high-burden countries. The partnership aims to reach a total of three million people with the drug by 2028. The initiative supports the Trump Administration's goal of eliminating mother-to-child HIV transmission.
What changed
The U.S. Department of State announced an expansion of its existing partnership with pharmaceutical company Gilead Sciences and international health organization The Global Fund to increase global access to lenacapavir, a twice-yearly injectable HIV prevention medication reported to be 99.9% effective in clinical trials. The partnership will now aim to reach an additional one million people, bringing the total commitment to three million people in high-burden countries by 2028.
For compliance professionals, this announcement reflects continued U.S. government investment in global health initiatives under PEPFAR. While this is an informational press release rather than a binding regulatory action, it signals ongoing U.S. support for HIV prevention programs internationally. No new compliance obligations or regulatory requirements are established for pharmaceutical companies, healthcare providers, or other private sector entities.
What to do next
- Monitor for updates on recipient country selection
- Review partnership fact sheets for implementation details
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Home Office of the Spokesperson Press Releases United States-Led Partnership to Provide an Additional One Million People with Landmark American HIV Drug Lenacapavir to Help End Mother-to-Child HIV Transmission
United States-Led Partnership to Provide an Additional One Million People with Landmark American HIV Drug Lenacapavir to Help End Mother-to-Child HIV Transmission
Media Note
April 14, 2026
Today, the U.S. Department of State announced the expansion of its partnership with Gilead Sciences and The Global Fund to increase access to lenacapavir (LEN), a breakthrough HIV prevention medication. LEN is a twice-yearly injectable medication, which has shown 99.9% effectiveness at preventing HIV in large-scale clinical trials. Expanding upon its initial market shaping investment in access to LEN, the Department is now growing its commitment to reach an additional 1 million people in high-burden countries with the two-dose annual regimen. Following today’s announcement, the United States and The Global Fund are committed to reach three million people in high-burden countries with LEN by 2028.
The Department of State will continue to prioritize the recipient countries based on countries’ HIV burden and the strength of the country’s existing infrastructure to distribute and deliver the drug. In coordination with partner national governments, the Department will continue to support complementary initiatives to promote uptake, strengthen health systems, and advance progress toward eliminating mother-to-child transmission of HIV under the Trump Administration’s America First Global Heath Strategy.
This expanded partnership reflects the United States’ enduring leadership in global health and President Trump’s continued investment in his goal of ending Mother-to-Child HIV transmission by the end of his second term.
Learn more about lenacapavir and the partnership with Gilead and The Global Fund through the original press release and the fact sheet.
Tags
Bureau of Global Health Security and Diplomacy Health HIV/AIDS Office of the Spokesperson
Related changes
Get daily alerts for State Dept Press Releases
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from DOS.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when State Dept Press Releases publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.